GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
Phase 1
Completed
- Conditions
- Respiratory Disorders
- Interventions
- Biological: Blood samplingBiological: GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.Biological: GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.Drug: Placebo
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 81
- Registration Number
- NCT03201211
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Assessment of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: CleanserOther: Test ProductOther: Sunscreen
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 123
- Registration Number
- NCT03197883
- Locations
- 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
Phase 4
Withdrawn
- Conditions
- Virus Diseases
- Interventions
- Biological: Rabipur
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03192371
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Phase 2
Withdrawn
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV vaccine (GSK3003891A) formulation 2Biological: RSV vaccine (GSK3003891A) formulation 3Drug: Placebo (Formulation buffer S9b)Biological: RSV vaccine (GSK3003891A) formulation 1
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03191383
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK2269557 500 µgDrug: GSK2269557 750 µg
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT03189589
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia
Phase 4
Terminated
- Conditions
- Diphtheria-Tetanus-Acellular Pertussis
- Interventions
- Other: Blood sample
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT03188458
- Locations
- 🇨🇴
GSK Investigational Site, Bogotá, Colombia
A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 111
- Registration Number
- NCT03184987
- Locations
- 🇯🇵
GSK Investigational Site, Toyama, Japan
Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel
Phase 4
Withdrawn
- Conditions
- Hepatitis A
- Interventions
- Biological: Havrix®
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03183492
Arnuity® Ellipta® Drug Use Investigation
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT03184480
- Locations
- 🇯🇵
GSK Investigational Site, Nagasaki, Japan
To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Facial micellar cleanser
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT03183518
- Locations
- 🇧🇷
GSK Investigational Site, Valinhos, Brazil
© Copyright 2025. All Rights Reserved by MedPath